GLP1-RAs and their place in the new T2D treatment algorithm

Australie

$0

gratuit

RACGP CPD Program

2 hr

Endocrinology

4 Credits

This course is expired! Browse All Courses
APPRENDRE ENCORE PLUS

Description du cours

The introduction of new treatments in diabetes, including injectable non-insulin glycemic modulators, creates new opportunities.

The position of GLP1RA agents in current Australian diabetes treatment algorithms requires GPs to re-think traditional models, including the role of these agents in combination with metformin or as an adjunct to other established treatments.

This program is supported by an independent educational grant provided from Eli Lilly.

Détails du cours

Date d'expiration : 2022-12-31

Métiers: Médecin

Faculté

Dr Marwan Obaid (Endocrinologist)
MBBS BSc(Med) FRACP MMed

A/Prof Gary Kilov (GP)
MBBCh
Launceston, TAS

Accréditation

This Active Learning Module has been approved by RACGP CPD Program for 4 CPD points.

Activity no. 219302

Members are able to claim CPD activity points for 4 points through ‘Quick log’ on their RACGP CPD Dashboard.

Objectif(s) d'apprentissage

Upon completion of this continuing education program participants will be better able to:

  • Individualising injectable therapy for patients with Type 2 diabetes
  • Evaluate the efficacy and safety of GLP 1 receptor agonists compared to insulin
  • Identify advantages of GLP1-RAs in specific patient groups compared to oral glucose-lowering medicines or insulin
This course is expired! Browse All Courses